Evidence map›Paper›PMID 39724143›Full record

ArticlePLoS genetics2024

Inhibitory KIRs decrease HLA class II-mediated protection in Type 1 Diabetes.

Laura Mora-Bitria, Bisrat J Debebe, Kelly L Miners, Kristin Ladell, Charandeep Kaur, James A Traherne, Wei Jiang, David A Price, Linda Hadcocks, Nicholas A R McQuibban and 5 more

Abstract read
In one paragraph

Article in PLoS genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Laura Mora-BitriaDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.ORCID 0000-0002-0850-1833
Bisrat J DebebeDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.
Kelly L MinersDivision of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, United Kingdom.
Kristin LadellDivision of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, United Kingdom.
Charandeep KaurDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.
James A TraherneImmunology Division, Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Wei JiangImmunology Division, Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
David A PriceDivision of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, United Kingdom.ORCID 0000-0001-9416-2737
Linda HadcocksInstitute for Infection and Immunity, St George's, University of London, London, United Kingdom.ORCID 0000-0003-1811-7146
Nicholas A R McQuibbanDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.
John TrowsdaleImmunology Division, Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
F Susan WongDivision of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, United Kingdom.
Nikolas PontikosUCL Institute of Ophthalmology, University College London, London, United Kingdom.ORCID 0000-0003-1782-4711
Christoph NiederaltSystems Pharmacology and Medicine, Bayer AG, Leverkusen, Germany.
Becca AsquithDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.ORCID 0000-0002-5911-3160

Funding

Wellcome Trust
6 · The paper itself

Abstract

Inhibitory killer cell immunoglobulin-like receptors (iKIRs) are a family of inhibitory receptors that are expressed by natural killer (NK) cells and late-stage differentiated T cells. There is accumulating evidence that iKIRs regulate T cell-mediated immunity. Recently, we reported that T cell-mediated control was enhanced by iKIRs in chronic viral infections. We hypothesized that in the context of autoimmunity, where an enhanced T cell response might be considered detrimental, iKIRs would have an opposite effect. We studied Type 1 diabetes (T1D) as a paradigmatic example of autoimmunity. In T1D, variation in the Human Leucocyte Antigen (HLA) genes explains up to 50% of the genetic risk, indicating that T cells have a major role in T1D etiopathogenesis. To investigate if iKIRs affect this T cell response, we asked whether HLA associations were modified by iKIR genes. We conducted an immunogenetic analysis of a case-control T1D dataset (N = 11,961) and found that iKIR genes, in the presence of genes encoding their ligands, have a consistent and significant effect on protective HLA class II genetic associations. Our results were validated in an independent data set. We conclude that iKIRs significantly decrease HLA class II protective associations and suggest that iKIRs regulate CD4+ T cell responses in T1D.

Indexed as

Diabetes Mellitus, Type 1Histocompatibility Antigens Class IIReceptors, KIRAutoimmunityCase-Control StudiesGenetic Predisposition to DiseaseHumansKiller Cells, NaturalT-LymphocytesHistocompatibility Antigens Class IIReceptors, KIR

Identifiers

PMID39724143
PMCPMC11741628

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.